Quiver Bioscience Secures Non-Dilutive Funding to Enhance CNS Genetic Medicine Drug Discovery Platform Capabilities and Advance Powerful AI/ML-Based In Vitro / In Silico Predictor of CNS Drug ...

The ADDF’s CFO discusses the areas that foundation is raising money for and how its reacting to the current economic ...

The funding will enable Stalicla to advance its autism-focused drug candidates, support asset partnering, prepare for its Series C financing, and cover general corporate activities. This investment in ...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland – June 30, 2025 – Addex Therapeutics (SIX: ADXN), a ...

Primary objective to determine optimal dosing schedule for a registrational trial Trial builds on recommended Phase 2 dose determined in co ...

Linda Aiken, PhD, RN, a prominent nurse researcher, has benefited significantly from funding from the National Institute of Nursing Research (NINR) throughout her distinguished career. NINR grants ...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland - June 30, 2025 - Addex Therapeutics(SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel ...

"A safe and effective therapeutic to address the epidemic of CNS metastases and specifically leptomeningeal ... Research Institute of Texas (CPRIT), the second largest public funding source for cancer ...

With the new SBIR funding, Quiver will further augment their existing ASO drug development capabilities by applying their platform to better prediction of ASO CNS toxicity using a combination of ...

The Society of NeuroInterventional Surgery (SNIS) convened the inaugural Neuro Interventional Oncology (NIO) summit at M D Anderson Cancer Center in Houston, Texas on April 26–27, 2024. Physician, ...

For decades, international researchers have received a small slice of the National Institutes of Health budget. In 2024, out ...